{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:18:21Z","timestamp":1791818301468,"version":"4.3.4"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007268","name":"Washington University in Saint Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.blre.2024.101184","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T17:14:21Z","timestamp":1709140461000},"page":"101184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?"],"prefix":"10.1016","volume":"65","author":[{"given":"Geoffrey L.","family":"Uy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay N.","family":"Lozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid G.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2024.101184_bb0005","author":"U.S. Food & Drug Administration"},{"issue":"7712","key":"10.1016\/j.blre.2024.101184_bb0010","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(71)91781-8","article-title":"Cytosine arabinoside in the treatment of acute myeloblastic leukaemia","volume":"297","author":"Bailey","year":"1971","journal-title":"Lancet"},{"issue":"5734","key":"10.1016\/j.blre.2024.101184_bb0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/bmj.4.5734.513","article-title":"Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia","volume":"4","author":"Crowther","year":"1970","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.blre.2024.101184_bb0020","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/1097-0142(197910)44:4<1189::AID-CNCR2820440404>3.0.CO;2-O","article-title":"High dose cytosine arabinoside (HDARAC) in refractory acute leukemia","volume":"44","author":"Rudnick","year":"1979","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.blre.2024.101184_bb0025","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood.V58.6.1203.1203","article-title":"Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B","volume":"58","author":"Rai","year":"1981","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2024.101184_bb0030","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.V77.8.1666.1666","article-title":"Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia","volume":"77","author":"Berman","year":"1991","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2024.101184_bb0035","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","article-title":"A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a southeastern Cancer study group study","volume":"10","author":"Vogler","year":"1992","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2024.101184_bb0040","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2024.101184_bb0045","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"issue":"16","key":"10.1016\/j.blre.2024.101184_bb0050","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2024.101184_bb0055","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41375-019-0472-2","article-title":"Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia","volume":"33","author":"Pollyea","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2024.101184_bb0060","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"10388","key":"10.1016\/j.blre.2024.101184_bb0065","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-first): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.blre.2024.101184_bb0070","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.blre.2024.101184_bb0075","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.5045\/br.2020.S003","article-title":"New agents in acute myeloid leukemia (AML)","volume":"55","author":"Park","year":"2020","journal-title":"Blood Res"},{"issue":"11","key":"10.1016\/j.blre.2024.101184_bb0080","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.3390\/cancers12113225","article-title":"Advances in acute myeloid leukemia: recently approved therapies and drugs in development","volume":"12","author":"Stanchina","year":"2020","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.blre.2024.101184_bb0085","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/nm.2969","article-title":"Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance","volume":"18","author":"Winkler","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.blre.2024.101184_bb0090","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/s41467-020-15817-5","article-title":"Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance","volume":"11","author":"Barbier","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.blre.2024.101184_bb0095","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0092-8674(91)90174-W","article-title":"Selectins: a family of adhesion receptors","volume":"67","author":"Bevilacqua","year":"1991","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.blre.2024.101184_bb0100","doi-asserted-by":"crossref","first-page":"14869","DOI":"10.1016\/S0021-9258(18)98555-8","article-title":"A carbohydrate domain common to both sialyl Le (a) and sialyl Le (X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1","volume":"266","author":"Berg","year":"1991","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.blre.2024.101184_bb0105","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/0006-291X(92)90697-J","article-title":"Comparison of L-selectin and E-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Lex and sialyl Lea","volume":"184","author":"Berg","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.blre.2024.101184_bb0110","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/S0021-9258(18)52267-5","article-title":"Structure and chromosomal location of the gene for endothelial-leukocyte adhesion molecule 1","volume":"266","author":"Collins","year":"1991","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.blre.2024.101184_bb0115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/hdy.2012.20","article-title":"An evolutionary history of the selectin gene cluster in humans","volume":"109","author":"Fumagalli","year":"2012","journal-title":"Heredity"},{"issue":"6","key":"10.1016\/j.blre.2024.101184_bb0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1471-4914(03)00071-6","article-title":"The role of selectins in inflammation and disease","volume":"9","author":"Ley","year":"2003","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.blre.2024.101184_bb0125","unstructured":"UniProt SELE entry P16581 LYAM2_HUMAN. Available from: https:\/\/www.uniprot.org\/uniprotkb\/P16581\/entry."},{"key":"10.1016\/j.blre.2024.101184_bb0130","unstructured":"UniProt SELP entry P16109 LYAM3_HUMAN. Available from: https:\/\/www.uniprot.org\/uniprotkb\/P16109\/entry."},{"key":"10.1016\/j.blre.2024.101184_bb0135","author":"UniProt SELL entry P14151 LYAM1_HUMAN"},{"key":"10.1016\/j.blre.2024.101184_bb0140","author":"e!Ensembleast Gene: SELE ENSG00000007908"},{"key":"10.1016\/j.blre.2024.101184_bb0145","unstructured":"e!Ensembleast Gene: SELL ENSG0000188404. Available from: https:\/\/useast.ensembl.org\/Homo_sapiens\/Gene\/Summary?g=ENSG00000188404;r=1:169690665-169711702."},{"key":"10.1016\/j.blre.2024.101184_bb0150","author":"e!Ensembleast Gene: SELP ENSG00000174175"},{"issue":"5","key":"10.1016\/j.blre.2024.101184_bb0155","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.0300-9475.2004.01413.x","article-title":"Modulation of adhesion molecule expression on endothelial cells after induction by lipopolysaccharide-stimulated whole blood","volume":"59","author":"Nooteboom","year":"2004","journal-title":"Scand J Immunol"},{"issue":"8","key":"10.1016\/j.blre.2024.101184_bb0160","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1091\/mbc.4.8.791","article-title":"Divergent fates of P-and E-selectins after their expression on the plasma membrane","volume":"4","author":"Subramaniam","year":"1993","journal-title":"Mol Biol Cell"},{"issue":"1","key":"10.1016\/j.blre.2024.101184_bb0165","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/jmcb\/mjv046","article-title":"E-selectin ligand complexes adopt an extended high-affinity conformation","volume":"8","author":"Preston","year":"2016","journal-title":"J Mol Cell Biol"},{"issue":"19","key":"10.1016\/j.blre.2024.101184_bb0170","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2017-05-783027","article-title":"Selectin catch-bonds mechanotransduce integrin activation and neutrophil arrest on inflamed endothelium under shear flow","volume":"130","author":"Morikis","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2024.101184_bb0175","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/imcb.12447","article-title":"Adhesion to E-selectin primes macrophages for activation through AKT and mTOR","volume":"99","author":"Davies","year":"2021","journal-title":"Immunol Cell Biol"},{"issue":"6","key":"10.1016\/j.blre.2024.101184_bb0180","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/01.RES.79.6.1196","article-title":"Distinct phenotype of E-selectin\u2013deficient mice: E-selectin is required for slow leukocyte rolling in vivo","volume":"79","author":"Kunkel","year":"1996","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.blre.2024.101184_bb0185","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/1074-7613(94)90041-8","article-title":"Characterization of E-selectin-deficient mice: demonstration of overlapping function of the endothelial selectins","volume":"1","author":"Labow","year":"1994","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.blre.2024.101184_bb0190","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.4049\/jimmunol.169.9.4797","article-title":"T cell requirement for development of chronic ulcerative dermatitis in E-and P-selectin-deficient mice","volume":"169","author":"Forlow","year":"2002","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.blre.2024.101184_bb0195","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood.V98.3.727.h8000727_727_735","article-title":"Dermal and pulmonary inflammatory disease in E-selectin and P-selectin double-null mice is reduced in triple-selectin\u2013null mice","volume":"98","author":"Collins","year":"2001","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2024.101184_bb0200","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1084\/jem.20101545","article-title":"Differential regulation of human and murine P-selectin expression and function in vivo","volume":"207","author":"Liu","year":"2010","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.blre.2024.101184_bb0205","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1182\/blood.V94.11.3820","article-title":"Divergent inducible expression of P-selectin and E-selectin in mice and Primates","volume":"94","author":"Yao","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101184_bb0210","series-title":"Advances in Cancer research","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/bs.acr.2022.07.001","article-title":"The biology of E-selectin ligands in leukemogenesis","author":"Ales","year":"2023"},{"issue":"12","key":"10.1016\/j.blre.2024.101184_bb0215","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/leu.2010.214","article-title":"The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization","volume":"24","author":"L\u00e9vesque","year":"2010","journal-title":"Leukemia"},{"issue":"7382","key":"10.1016\/j.blre.2024.101184_bb0220","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature10783","article-title":"Endothelial and perivascular cells maintain haematopoietic stem cells","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.blre.2024.101184_bb0225","doi-asserted-by":"crossref","first-page":"14423","DOI":"10.1073\/pnas.95.24.14423","article-title":"Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow","volume":"95","author":"Frenette","year":"1998","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.blre.2024.101184_bb0230","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1172\/JCI0214047","article-title":"Functional selectin ligands mediating human CD34+ cell interactions with bone marrow endothelium are enhanced postnatally","volume":"110","author":"Hidalgo","year":"2002","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.blre.2024.101184_bb0235","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1034\/j.1399-0004.2001.590110.x","article-title":"An HphI polymorphism in the E-selectin gene is associated with premature coronary artery disease","volume":"59","author":"Zheng","year":"2001","journal-title":"Clin Genet"},{"issue":"11","key":"10.1016\/j.blre.2024.101184_bb0240","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/hmg\/3.11.1935","article-title":"E-selectin polymorphism and atherosclerosis: an association study","volume":"3","author":"Wenzel","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10.1016\/j.blre.2024.101184_bb0245","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/hmg\/ddq057","article-title":"Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes","volume":"19","author":"Qi","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.blre.2024.101184_bb0250","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2141.2005.05701.x","article-title":"Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality","volume":"130","author":"Kato","year":"2005","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2024.101184_bb0255","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2009-12-260513","article-title":"GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice","volume":"116","author":"Chang","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2024.101184_bb0260","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.2022015797","article-title":"A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis","volume":"141","author":"Dampier","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2024.101184_bb0265","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.abb.2004.04.008","article-title":"The discovery, biology, and drug development of sialyl Lea and sialyl Lex","volume":"426","author":"Magnani","year":"2004","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"10.1016\/j.blre.2024.101184_bb0270","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/glycob\/1.4.318","article-title":"Letters to the Glyco-forum: the tumor markers, Sialyl Lea and Sialyl Lex bind ELAM-1","volume":"1","author":"Magnani","year":"1991","journal-title":"Glycobiology"},{"issue":"23","key":"10.1016\/j.blre.2024.101184_bb0275","doi-asserted-by":"crossref","first-page":"14365","DOI":"10.1016\/S0021-9258(19)45389-1","article-title":"A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II","volume":"257","author":"Magnani","year":"1982","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.blre.2024.101184_bb0280","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1373\/clinchem.2012.187047","article-title":"Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9","volume":"59","author":"Diamandis","year":"2013","journal-title":"Clin Chem"},{"issue":"4984","key":"10.1016\/j.blre.2024.101184_bb0285","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.1701274","article-title":"ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex","volume":"250","author":"Phillips","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.blre.2024.101184_bb0290","series-title":"CD15s (sLex) cluster report, in leucocyte typing V: White cell differentiation antigens","author":"Kannagi","year":"1995"},{"issue":"2","key":"10.1016\/j.blre.2024.101184_bb0295","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0016-5085(86)90930-3","article-title":"Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas","volume":"90","author":"Steinberg","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2024.101184_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799861","article-title":"The distinct roles of sialyltransferases in cancer biology and onco-immunology","volume":"12","author":"Hugonnet","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.blre.2024.101184_bb0305","doi-asserted-by":"crossref","first-page":"119R","DOI":"10.1093\/glycob\/11.10.119R","article-title":"Fucosyltransferases: structure\/function studies","volume":"11","author":"de Vries","year":"2001","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.blre.2024.101184_bb0310","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2014-07-588590","article-title":"ST3Gal-4 is the primary sialyltransferase regulating the synthesis of E-, P-, and L-selectin ligands on human myeloid leukocytes","volume":"125","author":"Mondal","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2024.101184_bb0315","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0092-8674(00)80137-3","article-title":"The \u03b1 (1,3) fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis","volume":"86","author":"Mal\u00fd","year":"1996","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.blre.2024.101184_bb0320","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1203\/00006450-200104000-00016","article-title":"Impairment of the Golgi GDP-L-fucose transport and unresponsiveness to fucose replacement therapy in LAD II patients","volume":"49","author":"Sturla","year":"2001","journal-title":"Pediatr Res"},{"issue":"6654","key":"10.1016\/j.blre.2024.101184_bb0325","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/40166","article-title":"Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells","volume":"389","author":"Fuhlbrigge","year":"1997","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.blre.2024.101184_bb0330","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1083\/jcb.153.6.1277","article-title":"CD44 is a major E-selectin ligand on human hematopoietic progenitor cells","volume":"153","author":"Dimitroff","year":"2001","journal-title":"J Cell Biol"},{"issue":"4","key":"10.1016\/j.blre.2024.101184_bb0335","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2005-05-2112","article-title":"CD43 is a ligand for E-selectin on CLA+ human T cells","volume":"107","author":"Fuhlbrigge","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101184_bb0340","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.leu.2404432","article-title":"Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice","volume":"21","author":"Ninomiya","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101184_bb0345","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2018-99-119449","article-title":"E-selectin ligand expression by leukemic blasts is associated with prognosis in patients with AML","volume":"132","author":"Chien","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101184_bb0350","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ijc.10566","article-title":"Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia","volume":"101","author":"Glenjen","year":"2002","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.blre.2024.101184_bb0355","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/10245330290028579","article-title":"L and E selectins in acute myeloid leukemia: expression, clinical relevance and relation to patient outcome","volume":"7","author":"Aref","year":"2002","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.blre.2024.101184_bb0360","first-page":"50","article-title":"Biochip Array technology and evaluation of serum levels of multiple cytokines and adhesion molecules in patients with newly diagnosed acute myeloid leukemia","volume":"36","author":"Horacek","year":"2014","journal-title":"Exp Oncol"},{"issue":"4","key":"10.1016\/j.blre.2024.101184_bb0365","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5507\/bp.2013.073","article-title":"Multi-analytical evaluation of serum levels of cytokines and adhesion molecules in patients treated for acute myeloid leukemia using biochip array technology","volume":"157","author":"Horacek","year":"2013","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"4","key":"10.1016\/j.blre.2024.101184_bb0370","doi-asserted-by":"crossref","first-page":"e60823","DOI":"10.1371\/journal.pone.0060823","article-title":"Leukemia mediated endothelial cell activation modulates leukemia cell susceptibility to chemotherapy through a positive feedback loop mechanism","volume":"8","author":"Pezeshkian","year":"2013","journal-title":"PloS One"},{"issue":"10","key":"10.1016\/j.blre.2024.101184_bb0375","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0145-2126(01)00036-4","article-title":"A minor E-selectin ligand, CD65, is critical for extravascular infiltration of acute myeloid leukemia cells","volume":"25","author":"Noguchi","year":"2001","journal-title":"Leuk Res"},{"issue":"21","key":"10.1016\/j.blre.2024.101184_bb0380","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.V124.21.620.620","article-title":"Vascular niche E-selectin protects acute myeloid Leukaemia stem cells from chemotherapy","volume":"124","author":"Winkler","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2024.101184_bb0385","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1182\/blood.V128.22.2823.2823","article-title":"Vascular E-selectin protects leukemia cells from chemotherapy by directly activating pro-survival NF-kb Signalling - therapeutic blockade of E-selectin dampens NF-kb activation","volume":"128","author":"Winkler","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2024.101184_bb0390","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-12-784132","article-title":"The interplay of leukemia cells and the bone marrow microenvironment","volume":"131","author":"Duarte","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101184_bb0395","series-title":"E-selectin antagonist compounds, compositions, and methods of use","author":"Magnani","year":"2018"},{"key":"10.1016\/j.blre.2024.101184_bb0400","series-title":"Crystal Structure of E-Selectin Lectin\/EGF Domains Complexed with SLeX (PDB ID: 1G1T)","author":"Somers","year":"2001"},{"issue":"3","key":"10.1016\/j.blre.2024.101184_bb0405","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0092-8674(00)00138-0","article-title":"Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P-and E-selectin bound to SLeX and PSGL-1","volume":"103","author":"Somers","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.blre.2024.101184_bb0410","unstructured":"GlycoMimetics Non-Clinical Research Report 1271-PC-0241, data on file at GlycoMimetics, Inc."},{"key":"10.1016\/j.blre.2024.101184_bb0415","unstructured":"GlycoMimetics Non-Clinical Research Report 1271-PC-0245, data on file at GlycoMimetics, Inc."},{"key":"10.1016\/j.blre.2024.101184_bb0420","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-141957","article-title":"Targeting E-selectin with GMI-1271 overcomes microenvironment-mediated resistance to venetoclax\/HMA therapy","volume":"136","author":"Chang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101184_bb0425","unstructured":"GlycoMimetics Non-Clinical Research Report 1271-NC-0018, data on file at GlycoMimetics, Inc."},{"key":"10.1016\/j.blre.2024.101184_bb0430","unstructured":"GlycoMimetics Non-Clinical Research Report 1271-PC-0244, data on file at GlycoMimetics, Inc."},{"issue":"12","key":"10.1016\/j.blre.2024.101184_bb0435","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1038\/leu.2017.123","article-title":"E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271","volume":"31","author":"Natoni","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2024.101184_bb0440","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3324\/haematol.10232","article-title":"Mucositis in patients with hematologic malignancies: an overview","volume":"92","author":"Niscola","year":"2007","journal-title":"Haematologica"},{"issue":"9 Suppl","key":"10.1016\/j.blre.2024.101184_bb0445","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/cncr.20162","article-title":"Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients","volume":"100","author":"Sonis","year":"2004","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.blre.2024.101184_bb0450","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.V122.21.2266.2266","article-title":"Administration of E-selectin antagonist GMI-1271 improves survival after high-dose chemotherapy by alleviating mucositis and accelerating neutrophil recovery","volume":"122","author":"Winkler","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2024.101184_bb0455","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood.2021010721","article-title":"Phase 1\/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia","volume":"139","author":"DeAngelo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101184_bb0460","unstructured":"GlycoMimetics Clinical Trial Report GMI-1271-101, data on file at GlycoMimetics, Inc."},{"issue":"23","key":"10.1016\/j.blre.2024.101184_bb0465","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood.V126.23.1004.1004","article-title":"First in human phase 1 single dose escalation studies of the E-selectin antagonist GMI-1271 show a favorable safety, pharmacokinetic, and biomarker profile","volume":"126","author":"Devata","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2024.101184_bb0470","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/rth2.12279","article-title":"Use of GMI-1271, an E-selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis","volume":"4","author":"Devata","year":"2020","journal-title":"Res Pract Thromb Haemostas"},{"issue":"22","key":"10.1016\/j.blre.2024.101184_bb0475","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1182\/blood.V128.22.3826.3826","article-title":"E-selectin antagonist GMI-1271 shows a favorable safety, PK and bleeding profile in phase I studies of healthy volunteers","volume":"128","author":"Angelini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101184_bb0480","unstructured":"GlycoMimetics Clinical Trial Report GMI-1271-104, data on file at GlycoMimetics, Inc."},{"key":"10.1016\/j.blre.2024.101184_bb0485","unstructured":"GlycoMimetics GMI-1271-201 Population Pharmacokinetic Analysis, data on file at GlycoMimetics, Inc."},{"key":"10.1016\/j.blre.2024.101184_bb0490","unstructured":"GlycoMimetics Clinical Trial Report GMI-1271-102, data on file at GlycoMimetics, Inc."},{"key":"10.1016\/j.blre.2024.101184_bb0495","series-title":"NONMEM Users Guide\u2013Part I Users Basic Guide","author":"Beal","year":"1989"},{"key":"10.1016\/j.blre.2024.101184_bb0500","unstructured":"GlycoMimetics Clinical Trial Report GMI-1271-201, data on file at GlycoMimetics, Inc."},{"issue":"18","key":"10.1016\/j.blre.2024.101184_bb0505","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","article-title":"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2024.101184_bb0510","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2024.101184_bb0515","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/bloodadvances.2017008227","article-title":"Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis","volume":"1","author":"Boddu","year":"2017","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101184_bb0520","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2023-185191","article-title":"Uproleselan added to Cladribine plus low dose Cytarabine (LDAC) in patients with treated secondary acute myeloid leukemia (TS-AML)","volume":"142","author":"Huante","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2024.101184_bb0525","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.blre.2024.101184_bb0530","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101184_bb0535","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1182\/blood-2022-168126","article-title":"A phase I study of uproleselan combined with azacitidine and venetoclax for the treatment of older or unfit patients with treatment na\u00efve acute myeloid leukemia","volume":"140","author":"Jonas","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2024.101184_bb0540","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.bbmt.2015.08.026","article-title":"A phase IIb, multicenter, open-label, safety, and efficacy study of high-dose, propylene glycol-free Melphalan hydrochloride for injection (EVOMELA) for Myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation","volume":"21","author":"Hari","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.blre.2024.101184_bb0545","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2007.14.7827","article-title":"High-dose Melphalan and the development of hematopoietic stem-cell transplantation: 25 years later","volume":"26","author":"Lazarus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2024.101184_bb0550","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty years of Melphalan use in hematopoietic stem cell transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2024.101184_bb0555","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","article-title":"Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model","volume":"38","author":"Grazziutti","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2024.101184_bb0560","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/bmt.2014.34","article-title":"N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial","volume":"49","author":"Moslehi","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101184_bb0565","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood-2023-179604","article-title":"Patient recorded outcomes from a randomized, controlled phase 2 trial of E-selectin inhibition with Uproleselan vs placebo to reduce GI toxicity during Melphalan-conditioned autologous hematopoietic cell transplantation for multiple myeloma","volume":"142","author":"Ryan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101184_bb0570","series-title":"A randomized, controlled phase 2 trial of Uproleselan, an E-selectin inhibitor, vs placebo to reduce GI toxicity in patients with multiple myeloma undergoing autologous hematopoietic cell transplant, in 20th international myeloma society annual meeting","author":"Crees","year":"2023"},{"key":"10.1016\/j.blre.2024.101184_bb0575","first-page":"1","article-title":"FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4\/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML","author":"Jia","year":"2023","journal-title":"Leukemia"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T15:27:04Z","timestamp":1713367624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":115,"alternative-id":["S0268960X24000171"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101184","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 GlycoMimetics, Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101184"}}